Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 18, 2023 16:39 ET | Source: Ocugen

Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results

MALVERN, Pa., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
June 30, 2023 08:00 ET | Source: Ocugen

Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly

MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
June 09, 2023 16:05 ET | Source: Ocugen

Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders

MALVERN, Pa., June 09, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
June 05, 2023 07:02 ET | Source: Ocugen

Ocugen, Inc. Announces Business Advisory Board

MALVERN, Pa., June 05, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
May 24, 2023 08:36 ET | Source: Ocugen

Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock

MALVERN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics,...
May 23, 2023 16:01 ET | Source: Ocugen

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

MALVERN, Pa., May 23, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics,...
May 23, 2023 08:00 ET | Source: Ocugen

Ocugen to Present at BIO International Convention 2023

MALVERN, Pa., May 23, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
May 05, 2023 07:00 ET | Source: Ocugen

Ocugen Provides Business Update with First Quarter 2023 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Announced Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400 for the Treatment of Retinitis Pigmentosa (RP) and...
April 28, 2023 07:00 ET | Source: Ocugen

Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results

MALVERN, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
April 27, 2023 07:25 ET | Source: Ocugen

Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies

MALVERN, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...